bob手机网页登录入口

07/2022

• Portfolio News

  Qiming's Portfolio Company InventisBio Lists on STAR Market

• Qiming News

  Qiming Venture Partners Announces Closing of US$3.2b Funds

06/2022

• Portfolio News

  OriCell Reports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at American Society of Clinical Oncology (ASCO) Annual Meeting 2022

05/2022

• Portfolio News

  WeRide received strategic investment from Bosch to jointly develop the auto grade and mass production of advanced driving solution in China

• Portfolio News

  Insilico Medicine Announced Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

• Portfolio News

  CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

• Portfolio News

  Clinical trial results of Belief BioMed's hemophilia B gene therapy drug candidate BBM-H901 published in The Lancet Haematology

• Portfolio News

  LaNova Medicines and Turning Point Therapeutics Enter into Licensing Agreement for LM-302 Antibody Drug Conjugate Program

• Portfolio News

  WeRide Reached Strategic Cooperation with Hesai, Leading the Application of Hybrid Solid-State Lidar on L4 Autonomous Vehicle

04/2022

• Portfolio News

  WeRide announces self-driving Robosweepers roll off the assembly line

• Portfolio News

  VenusP-Valve™ obtains CE marking under MDR and debuts in Europe as China's first valve product

• Qiming News

  Qiming’s Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List

03/2022

• Portfolio News

  Qiming’s Portfolio Company Rendu Biotechnology Lists on STAR Market

• Portfolio News

  Qiming’s Portfolio Company Arrail Group Lists on Main Board of HKEX

• Qiming News

  Qiming Monthly Newsletter (February 2022)

• Qiming News

  Retailers, Logistics Companies to Introduce Affordable Rapid Test Kits in Hong Kong

• Qiming News

  Qiming Venture Partners Welcomes David Chu as IR Partner

02/2022

• Portfolio News

  Convidecia Approved as Heterologous Booster in China

• Portfolio News

  Pluslife Biotech – A Greater Bay Area Company Launches First Handheld Covid-19 Nucleic Acid Test

• Qiming News

  Qiming Monthly Newsletter (November 2021 - January 2022)

01/2022

• Qiming News

  Qiming Venture Partners Announces Annual Promotions

• Portfolio News

  Qiming’s Portfolio Company Asieris Pharmaceuticals Lands on STAR Market

• Qiming News

  Shiyu Wang Rejoins Qiming Venture Partners as Partner Co-Leads TMT Team

12/2021

• Qiming News

  Qiming Venture Partners to Hold 13th CEO Summit This Week

11/2021

• Qiming News

• Qiming News

10/2021

• Portfolio News

• Portfolio News

  ShouTi Secures $100 Million Series B Financing, Qiming Participated

• Qiming News

  Qiming Monthly Newsletter October

• Qiming News

• Portfolio News

• Portfolio News

• Portfolio News

  Qiming’s Portfolio Company Microtech Medical Lists on Main Board of HKEx

• Portfolio News

  Qiming’s Portfolio Company Abbisko Lists on Main Board of HKEx

09/2021

• Portfolio News

  Qiming’s Portfolio Company Broncus Lists on Main Board of HKEx

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

  Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market

• Qiming News

• Qiming News

  Qiming Venture Partners Monthly Newsletter | August

08/2021

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

  Qiming’s Portfolio Company Sino Biological Lists on Shenzhen’s ChiNext Market

• Portfolio News

• Portfolio News

  Belief Biomed's Gene Therapy for Hemophilia B Receives NMPA IND Approval

• Portfolio News

  Antengene, MindRank AI to Jointly Develope Difficult-to-Drug Molecular Targets

• Qiming News

  Qiming Venture Partners Monthly Newsletter | July

• Portfolio News

  Berry Oncology Completes Series B1 Funding

• Portfolio News

  Asia's Leading Crypto Financial Services Platform Matrixport Valued at Over $1 Billion

• Portfolio News

  Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

07/2021

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News

• Portfolio News